Latest News

Each news article below shows only part of the news story. To view the full story, click on Read More below the story. 

  • May 13, 2019 9:51 AM | Deleted user

    May 13, 2019, HealthDay News

    New recommendations have been developed for breast cancer screening based on a life-years-gained model; the American Society of Breast Surgeons (ASBrS) official statement. The guideline recommendations state that women older than 25 years should undergo formal risk assessment for breast cancer. Yearly screening mammography should be initiated at age 40 years among women with an average risk for breast cancer. Women with higher-than-average risk should undergo yearly screening mammography and be offered yearly supplemental imaging, with initiation based on risk. When life expectancy is less than 10 years, screening mammography should cease. 

    Read more.

  • May 10, 2019 9:48 AM | Deleted user

    May 10, 2019, Healio 

    Due to significantly higher rates of steatosis and liver imaging, researchers linked intrahepatic cholestasis of pregnancy and nonalcoholic fatty liver disease. Tatyana Kushner, MD, MSCE, from the Icahn School of Medicine at Mount Sinai in New York discussed the findings during a press conference call on behalf of co-author Erica Monrose, MD, from the Icahn School of Medicine, who will present the study at Digestive Disease Week in San Diego. 

    Read more.

  • May 10, 2019 9:44 AM | Deleted user

    May 10, 2019, R&D  

    Artificial intelligence (AI) could help doctors predict breast cancer risk earlier and tailor care options to individual patients based on risk. Researchers from the Massachusetts Institute of Technology's (MIT) Computer Science and Artificial Intelligence Laboratory (CSAIL) have developed a new technique using a deep-learning model that predicts if a patient is likely to develop breast cancer as much as five years in the future. 

    Read more.

  • May 10, 2019 9:42 AM | Deleted user

    May 10, 2019, Primary Care Today  Healio

    Making the distinction between the different types of abnormal uterine bleeding is critical to ensure proper treatment, according to a presentation at the American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting. Health care costs, lost productivity costs, and lost work wages associated with the symptom can total more than $12 billion annually, Kristen A. Matteson, MD, MPH, associate professor of obstetrics and gynecology, Women and Infants Hospital and Warren Alpert Medical School of Brown University, told attendees.  

    Read more.

  • May 07, 2019 10:22 AM | Deleted user

    May 2, 2019, MedPage Today  

    NASHVILLE -- A point-of-care ultrasound device performed comparable to diagnostic imaging read by ob/gyn sonographers in identifying gynecologic pathology, and could have applicability in low-resource settings, a researcher said here. 

    Read more.

  • May 07, 2019 10:06 AM | Deleted user

    May 7, 2019, HemOnc Today 

    Physicians may be able to predict which patients with HER2-positive breast cancer can safely forgo surgery based on tumor hormone status, imaging results after neoadjuvant chemotherapy and ductal carcinoma in situ on initial biopsy, according to study results presented at American Society of Breast Surgeons Annual Meeting.  

    Read more.

  • May 07, 2019 9:53 AM | Deleted user

    There’s an App for That: Increasing HPV Vaccination Rates

    Tuesday, May 21 at 2 PM CST

    Join NAO for a webinar on the benefits of using the HPV Same Way Same Day app as a clinical training tool to increase HPV vaccination rates. Presenter Dr. Sharon Humiston, MPH, FAAP will discuss practice techniques to introduce and how to discuss the vaccine with parents and young patients, including those who may be hesitant to immunize. 

    Register Here.

  • May 06, 2019 10:28 AM | Deleted user

    May 6, 2019, MedPage Today OB/GYN Update 

    Healthcare workers who object to participating in certain services or procedures "on account of religious beliefs or moral convictions" will have an easier time asserting their rights under a final rule issued Thursday by the Department of Health and Human Services.

    Read more.

  • May 03, 2019 8:58 AM | Deleted user

    May 2, 2019, MedPage Today 

    Dropping chemotherapy from a first-line regimen of trastuzumab (Herceptin) and pertuzumab (Perjeta) didn't compromise overall survival at 2 years in advanced HER2-positive breast cancer, although disease progression resumed much faster, a randomized phase II trial found. 

    Read more.

  • May 03, 2019 8:55 AM | Deleted user

    May 3, 2019, HemOnc Today 

    Detection of persistent HPV DNA in oral rinses appeared associated with greater risk for disease recurrence and death among patients with HPV-positive oral and oropharyngeal squamous cell carcinoma, according to study results published in JAMA Oncology. The results suggest HPV DNA has potential as a biomarker for progression risk and treatment response among this patient population. 

    Read more. 

Powered by Wild Apricot Membership Software